Supreme Court on Drug Price Control and Right to Life

Context:

On October 27, 2026, the Supreme Court of India observed that economic policy cannot take precedence over citizens’ lives while examining the regulation of essential medicine prices. The Court questioned the Centre and the National Pharmaceutical Pricing Authority (NPPA) over excessive trade margins and weak enforcement of drug-price controls.

Key Developments:

• • • The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins on 137 non-scheduled anti-cancer medicines at 30% of their maximum retail price (MRP), with the revised prices scheduled to take effect from November 9, 2026. The Court questioned why the 16% retailer margin prescribed under the Drugs (Prices Control) Order, 2013 (DPCO) should not apply more broadly to essential medicines.
    • The Centre advocated a calibrated approach, arguing that complete government control over medicine prices could adversely affect investment, innovation and competition. Hospitals also contended that reducing medicine margins could threaten their financial viability and lead to higher charges for other services. The Supreme Court reserved its order and allowed the parties two weeks to submit written arguments.

Drug Price Regulation in India:

• • • The Drugs (Prices Control) Order, 2013, issued under the Essential Commodities Act, 1955, provides the framework for regulating prices of specified medicines. The NPPA, functioning under the Department of Pharmaceuticals, monitors drug prices and enforces applicable controls.
    • Scheduled formulations are generally subject to government-fixed ceiling prices, while non-scheduled formulations are governed by other applicable provisions, including restrictions on price increases.
    • The National Pharmaceutical Pricing Authority is an independent regulatory agency of the Government of India, established on August 29, 1997. It functions under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, and is headquartered in New Delhi. Its legal mandate derives from the Drugs (Prices Control) Order issued under Section 3 of the Essential Commodities Act, 1955.

Major Issues:

High medicine prices increase out-of-pocket expenditure and may push vulnerable households into debt. Weak enforcement and delayed recovery of overcharged amounts reduce regulatory effectiveness. At the same time, excessively restrictive price controls may affect pharmaceutical investment and innovation. The classification of essential medicines and the transparency of hospital billing also require evidence-based standards to prevent excessive markups and unjustified cost-shifting.

Way Forward:

The government should strengthen the NPPA’s monitoring, enforcement and recovery mechanisms and periodically review the list of essential medicines using transparent criteria. Evidence-based price ceilings should balance affordability with reasonable industry returns. Expanding generic medicines, public procurement and Jan Aushadhi Kendras can improve access. Transparent hospital billing, monitoring of service charges and support for pharmaceutical research are also essential.

Conclusion:

Affordable medicines are essential to making the right to life meaningful. India needs effective price regulation, stronger enforcement and transparent healthcare billing while preserving incentives for pharmaceutical innovation. The ultimate objective should be to ensure that access to life-saving treatment depends less on economic status and more on medical need.